Vaxart, Inc. Expense Breakdown
No Expense Breakdown for VXRT on this site yet.
- 2026-06-30: Single Reportable $6.60M.
- 2025-06-30: Single Reportable $4.60M.
Source checked: the stored Expense Breakdown page for VXRT.
Expenses by product
General and Administrative Expense: each quarter (3 month)
| Quarter end | Single Reportable |
|---|---|
| 2026-06-30 | $6.60M |
| 2025-06-30 | $4.60M |
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | Single Reportable |
|---|---|
| 2026-06-30 | $29.00K |
| 2025-06-30 | $20.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |